Shionogi Of Japan Expects Peramivir Approval In January For Flu
This article was originally published in PharmAsia News
Japan's Shionogi expects to begin selling peramivir, an intravenous flu drug, in Japan as early as January, when the company hopes to receive health ministry approval
You may also be interested in...
Lupin hopes a surge in demand for albuterol sulphate due to increased off-label use in COVID-19 patients will help its generic version, which is likely to be launched in the first half of FY21. But the Indian firm may recall a batch of metformin after the US FDA recently asked a few companies to retract extended-release versions due to NDMA concerns.
Takeda is confident about the promise of its first-in-class molecule for higher-risk myelodysplastic syndromes after positive Phase II data.
Medtech insiders offer 10 strategies for medtech companies to rethink their businesses. See what Ernst & Young’s global health sciences and wellness leader Pamela Spence said about it here.